Product Description: ALK-IN-1 (Brigatinib analog) is a highly efficient and selective inhibitor of ALK kinase, derived from patent US20140066406 A1.
Applications: Cancer-Kinase/protease
Formula: C26H34ClN6O2P
References: [1]Sen Zhang, Frank Wang, Jeffrey Keats, Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research: April 15, 2010; Volume 70, Issue 8, Supplement 1/[2]Victor M. Rivera, Frank Wang, Rana Anjum, Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1
CAS Number: 1197958-12-5
Molecular Weight: 529.01
Compound Purity: 99.94
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Anaplastic lymphoma kinase (ALK)
Deutsch
English
